No testosterone patches are sold in the United States today. Every guide we write starts from the regulatory record, and on this one the record is unusually clean. Three patches received marketing approval between 1993 and 1997. Every strength of all three now carries discontinued status.
The Verdict
Whether Any Testosterone Patch Is Still Sold
There is currently no prescription testosterone patch available in American pharmacies. The Food and Drug Administration (FDA) approved three transdermal patch systems in the 1990s. Testoderm, approved in 1993, was a scrotal patch. Androderm followed in 1995 as a non-scrotal system applied to the torso or upper arms. Testoderm TTS gained approval in 1997.
A query of the Drugs@FDA database reveals that every dose of all three brand applications is listed as discontinued. No manufacturer ever gained approval for an abbreviated new drug application for a generic testosterone patch. The National Drug Code Directory contains zero active listings for testosterone in an extended-release transdermal film. Patients searching for a patch find nothing to fill. Manufacturing stopped across all three brand lines.
| Brand name | Approval date | Application type | Current marketing status |
|---|---|---|---|
| Testoderm (scrotal system) | 12 October 1993 | Scrotal system, 4 mg and 6 mg daily | Discontinued |
| Androderm | 29 September 1995 | Non-scrotal system, 2 mg, 2.5 mg, 4 mg, 5 mg daily | Discontinued |
| Testoderm TTS (non-scrotal system) | 18 December 1997 | Non-scrotal system, 5 mg daily | Discontinued |
Regulatory Records and the Formal Safety Determination
The removal of testosterone patches from commercial distribution did not stem from a regulatory safety revocation. On 1 November 2023, the FDA published a formal determination in the Federal Register regarding Androderm. The agency concluded that Androderm was not withdrawn from sale for reasons of safety or effectiveness.
That finding allows the agency to approve future generic applications referencing Androderm if a company chooses to submit one. The Federal Register notice establishes that the patch was already off the market by late 2023. Neither the FDA nor the manufacturer published an official discontinuation date. The product exited production quietly as market demand collapsed.
Documented Skin Reactions and Tolerability Evidence
Application site skin irritation was the primary clinical complication documented in patch trials. In clinical trials for the lower-dose Androderm systems, 28% of participants reported localized skin reactions. Pruritus affected 17% of trial participants. Blistering vesicles occurred in 6% of subjects. Trials evaluating earlier, higher-strength systems showed an overall application site reaction rate of 48%.
Within that cohort, 37% experienced itching, 12% developed blistering, and 7% exhibited erythema. The prescribing information noted that mild redness occurred in a majority of men at some point during therapy. Patients applying patches over bony prominences experienced burn-like blister reactions.
A persistent rumor claims that 10% to 15% of men stopped the patch due to irritation. That exact statistic does not appear anywhere in the FDA prescribing documentation or primary trial publications. A 60-man crossover trial evaluated why these dermal reactions occurred. Allergic contact dermatitis developed in 12% of men wearing non-scrotal systems. Zero men developed confirmed allergic contact dermatitis using the scrotal patch.
Four men allergic to the non-scrotal system tolerated the scrotal patch without incident. Researchers concluded that adhesive chemicals and alcohol absorption enhancers provoked the immune response rather than testosterone itself. Our review of TRT side effects and risks outlines systemic reactions compared to localized patch problems.
| Adverse reaction type | Incidence in lower-dose trial (N = 36) | Incidence in higher-dose trial (N = 122) |
|---|---|---|
| Any application site reaction | 28% | 48% |
| Application site pruritus (itching) | 17% | 37% |
| Blistering reactions | Not reported (>3%) | 12% |
| Application site vesicles | 6% | 6% |
| Erythema (redness) | Not reported (>3%) | 7% |
| Contact dermatitis to system | Not reported (>3%) | 4% |
| Burning sensation or induration | Not reported (>3%) | 3% each |
Pharmacokinetics and the Diurnal Curve Debate
Transdermal patches delivered continuous hormone absorption with rapid systemic clearance upon removal. Applied nightly, the 4 mg system sustained circulating testosterone concentrations within the physiological reference range of 300 to 1030 ng/dL. Peak absorption occurred at a median of 8 hours post-application. When patients removed the system, serum hormone levels declined with an apparent half-life of 70 minutes. Baseline hypogonadal concentrations returned within 24 hours.
Medical reviews frequently claim that patches uniquely replicate the natural diurnal testosterone rhythm seen in healthy young men. That circadian framing comes exclusively from review literature. The FDA label contains neither the word circadian nor diurnal. The label promises steady 24-hour delivery rather than chronobiological mimicry.
Showering three hours after application altered serum concentrations by less than 1%. Patches incorporated a metallic backing layer containing aluminum. Because magnetic fields induce electrical currents in conductive metals, the label advised removing patches prior to MRI scans to avoid skin burns. For tracking your levels during therapy, a dedicated men's hormone panel provides baseline and mid-treatment values.
Market Shifts and Commercial Prescribing Trends
Commercial prescription tracking reveals a steep decline in testosterone patch utilization between 2003 and 2013. A MarketScan database study published in The Journal of Urology tracked prescribing patterns among 18-to-45-year-old men. In 2003, patches accounted for 22.3% of all testosterone prescriptions in that cohort. By 2013, patch market share plummeted to 4.2%.
Over that decade, injection share climbed from 20.7% to 56.1%. Topical gels dropped from 66.8% to 44.6%. Subcutaneous pellets expanded from under 1% to 3.9%. The study authors linked the shift toward injections to insurance restrictions on branded topicals and the convenience of less frequent dosing. The authors evaluated prescribing dynamics across all forms rather than studying why patches specifically declined.
The clinical literature indicates that high rates of adhesive irritation combined with the convenience of once-weekly injections marginalized transdermal systems. A separate clinical debate centers on muscular outcomes across delivery routes. A meta-analysis reported superior muscle mass and strength gains with intramuscular therapy compared to transdermal administration. However, trial designs created a significant confounding variable.
Injection protocols routinely delivered substantially higher cumulative milligram doses than transdermal systems. Total bioavailable dose, rather than route mechanics, explains the observed difference in physical outcomes. Readers balancing procedural discomfort against application routines can examine testosterone injection pain.
| Formulation type | 2003 market share | 2013 market share | Direction of shift |
|---|---|---|---|
| Transdermal patches | 22.3% | 4.2% | Decreased by 18.1 percentage points |
| Intramuscular injections | 20.7% | 56.1% | Increased by 35.4 percentage points |
| Topical gels | 66.8% | 44.6% | Decreased by 22.2 percentage points |
| Subcutaneous pellets | <1.0% | 3.9% | Increased by approximately 3.0 percentage points |
Secondary Exposure Differences Between Patches and Gels
Enclosed adhesive systems prevented interpersonal hormone transfer more effectively than topical gels. Topical testosterone gels carry a prominent boxed warning regarding secondary exposure risks. Surveillance programs recorded virilization in children who came into direct physical contact with unwashed application areas on adult male users.
Reported symptoms included genital enlargement, premature pubic hair development, aggressive behavior, and accelerated bone age. Some pediatric skeletal changes proved irreversible. In contrast, the Androderm prescribing information never carried a boxed warning. The patch label omitted secondary exposure restrictions because the active hormone remained sealed behind an impermeable backing membrane.
Users could shower, exercise, or engage in sexual intimacy without removing the transdermal film. The only warning instructed patients to avoid direct exposure of pregnant women to the patch surface. No published clinical trial has established a numeric transmission ratio comparing patches to gels. The structural difference in delivery mechanics eliminated the residue transfer that complicates daily gel application. For female hormone therapy, a parallel comparison exists in our analysis of estradiol patch vs pill options.
The Relabelling Disconnect and Cardiovascular Language
Discontinued testosterone formulations remain frozen under outdated regulatory safety warnings. On 28 February 2025, the FDA announced comprehensive class-wide labelling updates across all active testosterone products. This mandate integrated evidence from the landmark TRAVERSE trial.
FDA stated that the trial concluded there was no increase in the risk of adverse cardiovascular outcomes in men using testosterone for hypogonadism. Consequently, the FDA ordered the removal of cardiovascular risk warnings from the Boxed Warning section of marketed products. Simultaneously, the agency mandated new warnings regarding blood pressure elevations observed across ambulatory monitoring trials.
Active products like AndroGel updated their packaging inserts in July 2025. Androderm missed this regulatory modernization entirely. The final approved label supplement for Androderm dates to 11 May 2020. Because the manufacturer ceased commercial marketing before the 2025 directive, the archived label still warns of myocardial infarction and stroke risks. Clinicians reviewing historic patch documents see obsolete cardiovascular cautions that regulators have removed from active medications.
Currently Approved Formulations and Market Corrections
Patients exploring testosterone replacement therapy today select from several distinct delivery mechanisms. Injectable options represent the most common modality. Prescribers write for generic testosterone cypionate intramuscular injections or weekly subcutaneous autoinjectors. Transdermal gels remain widely distributed in multiple concentrations.
Oral formulations using testosterone undecanoate provide non-invasive dosing absorbed via intestinal lymphatic pathways. Subcutaneous crystalline pellets provide continuous hormone release over several months. Two persistent market myths require clarification.
First, there is no FDA-approved testosterone cream currently sold in the United States. Topical creams dispensed by compounding pharmacies are custom formulations that bypass standard regulatory approval. Our guide to compounded vs brand testosterone analyzes the testing and quality differences between these sources.
Second, there is no marketed FDA-approved buccal testosterone product. The sole approved buccal system, Striant, carries discontinued status in Drugs@FDA. Transdermal metered axillary solutions continue as generic preparations after the original brand Axiron exited distribution in 2018.
The 2018 Endocrine Society Clinical Practice Guideline notes that therapy can begin with any approved formulation based on patient preference, cost, and treatment burden. Our comprehensive breakdown of TRT injections, cream, and pellets compares dosing schedules and convenience. To determine when therapeutic benefits become noticeable, read our timeline on how long TRT takes to work.
The Regulatory Verdict on Testosterone Patches
The commercial departure of transdermal patches reflects practical patient tolerability rather than pharmacological failure. Testosterone patches delivered dependable hormone levels without secondary exposure hazards, but high rates of localized dermal inflammation made long-term adherence difficult. Commercial insurers favored generic injectables, and patients preferred weekly injections or non-irritating gels over daily adhesive applications.
Who this analysis does not serve: Patients experiencing unexplained fatigue or seeking personalized medical evaluation require diagnostic testing by a physician. What would change our answer: An Abbreviated New Drug Application approval for a generic testosterone patch would place the delivery system back onto commercial pharmacy shelves. Until a pharmaceutical sponsor navigates that pathway, transdermal patches remain unavailable to American consumers. No prescriber can choose a patch today, because no strength of any of the three brands remains in distribution.
Frequently Asked Questions
Are testosterone patches still available in 2026?
No, testosterone patches are not available in pharmacies in 2026. The Food and Drug Administration approved three transdermal patch products between 1993 and 1997: Testoderm, Androderm, and Testoderm TTS. Every strength of all three brand applications currently carries discontinued status in the official Drugs@FDA database. No manufacturer ever secured approval for a generic version under an abbreviated new drug application. The FDA National Drug Code Directory contains zero active distribution records for transdermal film testosterone systems. Patients seeing patches referenced in older clinical guidelines cannot fill a prescription for one today because manufacturing ceased across all brand lines.
Why was Androderm discontinued?
Androderm was discontinued due to commercial factors and declining prescription volume rather than a government ban. Between 2003 and 2013, transdermal patch market share dropped from 22.3% of testosterone prescriptions to just 4.2% among reproductive-age American men. Over that same decade, injectable testosterone expanded significantly due to insurance preference and simpler dosing schedules. Androderm also suffered from documented patient tolerability challenges. Clinical trials recorded that 28% of men using modern formulations and 48% using earlier strengths developed localized skin irritation, itching, or blistering. Faced with dwindling demand and high rates of treatment discontinuation, the manufacturer retired the product.
Were testosterone patches taken off the market for safety reasons?
No, testosterone patches were not taken off the market for safety reasons. On 1 November 2023, the Food and Drug Administration published a formal finding in the Federal Register specifically addressing Androderm. The regulatory agency determined that the product was not withdrawn from sale for reasons of safety or effectiveness. This legal ruling confirms that the medication possessed an acceptable safety profile throughout its marketing lifespan. The determination also permits pharmaceutical companies to submit abbreviated new drug applications to produce generic patches in the future. Commercial withdrawal was entirely an economic and manufacturing decision made by the brand sponsor.
How bad were the skin reactions with testosterone patches?
Skin reactions from testosterone patches were frequent and clinically significant. In FDA clinical trials for the later 2 mg and 4 mg Androderm formulations, 28% of subjects reported application site reactions, with 17% reporting application site pruritus and 6% developing vesicles. In trials of the original higher-strength patches, 48% developed skin reactions, including 37% with pruritus, 12% with blistering, and 7% with erythema. Transient redness occurred in the majority of patients. A 60-subject crossover study revealed that adhesive chemicals and alcohol enhancers caused these allergic contact reactions rather than the testosterone molecule, as men allergic to non-scrotal patches tolerated scrotal systems without irritation.
Do testosterone patches transfer to other people like gels do?
Testosterone patches did not present the interpersonal transference risks associated with topical gels. Gels leave active testosterone on the surface of the skin after application, requiring a strict boxed warning regarding accidental transfer to children and women through physical contact. In contrast, transdermal patches sealed the hormone beneath an impermeable backing layer. The Androderm prescribing information never carried a boxed warning for secondary exposure. The official instructions stated that patients did not need to remove the patch during showering, bathing, or sexual intercourse. The only related warning cautioned against direct exposure of pregnant women to the patch surface.
What replaced the testosterone patch?
Patients who previously used patches have shifted toward other transdermal and systemic formulations. Topical testosterone gels applied to the shoulders or thighs represent the most common non-invasive substitute, maintaining stable daily hormone levels despite requiring precautions against skin-to-skin transfer. Intramuscular and subcutaneous testosterone injections provide weekly or bi-weekly dosing that avoids daily application routines entirely. Modern oral testosterone undecanoate capsules offer an effective needle-free alternative absorbed through the intestinal lymphatic system without liver toxicity. Long-acting subcutaneous pellets implanted every three to six months provide continuous release for men seeking minimal procedural burden.
Is there an FDA-approved testosterone cream?
There is no FDA-approved testosterone cream marketed in the United States. A search of the Drugs@FDA database for testosterone in a cream dosage form yields zero results. Any testosterone cream obtained by patients is a compounded preparation prepared by specialized compounding pharmacies rather than a commercially manufactured, FDA-reviewed medication. While physicians frequently prescribe compounded testosterone creams off-label, these formulations do not undergo federal review for batch uniformity, stability, or clinical efficacy. Patients seeking an approved topical formulation must choose an FDA-approved transdermal gel or a generic transdermal metered axillary solution.